表紙
市場調查報告書

頭部頸部癌症:市場預測和分析(至2024年)

Head and Neck Cancer Disease Coverage Forecast and Market Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 939971
出版日期 內容資訊 英文 83 Pages
商品交期: 最快1-2個工作天內
價格
頭部頸部癌症:市場預測和分析(至2024年) Head and Neck Cancer Disease Coverage Forecast and Market Analysis to 2024
出版日期: 2020年06月19日內容資訊: 英文 83 Pages
簡介

該報告分析了全球頭頸癌治療藥物的臨床狀況和市場趨勢展望,並概述了疾病,流行病學預測和當前的主要治療藥物(已推出/已上市的產品)。以及臨床試驗進度,當前未滿足的需求和未來的市場機會,以及有關臨床試驗/市場前景的專家意見。

目錄

第1章概述

第二章疾病背景

  • 定義
  • 患者分類
  • 風險因素
  • 症狀
  • 診斷

第3章治療

  • 介紹模式
  • 標準治療:按疾病進展階段
  • 局部晚期疾病的首選全身治療方案
  • 高度系統疾病的首選全身療法
  • 批准的非處方藥

第四章流行病學

  • 案例分析方法

第5章非處方藥

第6章流水線藥物

按地區劃分的第7章主要監管事件

第8章成功的可能性

第9章許可協議/資產收購交易

第10章臨床試驗環境

  • 研究客戶分類:按情況
  • 研究客戶分類:按階段
  • 近期趨勢

第11章藥物評估模型

第12章市場動態

第13章未來趨勢

  • 標準治療:過渡到免疫治療
  • Keytruda的主導地位:通過標籤擴展得到鞏固
  • 競爭批准成為HNSCC診斷代理
  • 對轉移性和復發性HNSCC的聯合免疫療法的興趣日益濃厚
  • 其他新方法:落後於免疫檢查點抑製劑

第14章共識預測

第15章最近的市場趨勢和分析師觀點

第16章未來的主要市場趨勢

第17章KOL(專家)視圖

第18章參考文獻

  • 處方藥信息

第19章附錄

目錄
Product Code: DMKC0214483

Latest key takeaways

Datamonitor Healthcare estimates that in 2018, there were 880,700 incident cases of head and neck cancer (HNC) worldwide, and expects that number to increase to 967,000 incident cases by 2027. The majority of HNC diagnoses (75.2%) worldwide are in males, ranging from 64.9% to 76.3% across regions.

Though a heterogenous group of diseases, the overwhelming majority (90%) of HNCs are comprised of squamous cell carcinomas of the head and neck (HNSCCs).

Most HNC patients are treated with surgery, radiotherapy, and/or platinum-based chemotherapy.

Erbitux, once among the dominant branded systemic therapies for HNC, is being eclipsed by newer checkpoint inhibitors. Erbitux is approved for use in combination with radiation therapy to treat patients with unresectable SCCHN and both first- and subsequent-line recurrent/metastatic SCCHN as monotherapy and in combination with chemotherapy.

HNSCC tumors are highly immunogenic and have elevated expression of immune checkpoint modulators. As such, there has been much interest in the development of immunotherapies to allow for a more targeted treatment program.

The first immunotherapies approved for recurrent/metastatic HNSCCs are the checkpoint inhibitors Keytruda (for first and second line) and Opdivo (second line only). They have quickly established themselves as the most successful marketed drugs in this treatment setting. Keytruda is approved for second-line patients with a tumor proportion score (TPS) of >50%, while Opdivo has no such restrictions.

Setbacks in the pipeline for treatments being developed for recurrent/metastatic HNSCCs, such as Imfinzi and Gilotrif, and, most recently, the suspension of JAVELIN 100 (which tested Bavencio combined with chemoradiotherapy for non-resectable HNSCC), have allowed Keytruda and Opdivo to consolidate their leading positions in this setting.

Keytruda is favored by American physicians, and unlike Opdivo, is available for first- as well as second-line intervention for recurrent/metastatic HNSCC. However, Keytruda is not broadly available in the UK in the first-line setting due to a recent rejection by NICE, and Opdivo is typically favored by British physicians in the second-line setting.

The ongoing Phase III CheckMate-651 trial seeks to gain approval for Opdivo for first-line recurrent/metastatic HNSCC, and challenge Keytruda in this setting.

Keytruda is in Phase III trials in the lucrative, newly diagnosed, locally advanced HNSCC setting. KEYNOTE-412 is evaluating Keytruda combined with chemoradiation and as maintenance therapy for non-resectable HNSCC, while KEYNOTE-689 is evaluating Keytruda as neoadjuvant therapy and in combination with standard-of-care adjuvant therapy for resectable HNSCC. Keytruda is also seeking its first approval for nasopharyngeal cancer. KEYNOTE-122 is evaluating Keytruda versus standard-of-care chemotherapy for recurrent/metastatic nasopharyngeal cancer. Success in these areas would result in unrivaled availability for Keytruda across the HNC treatment landscape.

The other checkpoint inhibitor in Phase III development for newly diagnosed, locally advanced HNSCCs is Tecentriq. IMvoke010 is evaluating Tecentriq as single-agent adjuvant therapy for resectable, locally advanced HNSCC. IMvoke010 may offer an attractive alternative by using checkpoint inhibition as a monotherapy in locally advanced HNSCC, thereby avoiding the toxicity of platinum-based chemotherapy.

Immunotherapy approaches outside of checkpoint inhibitors, such as targeted T-cell therapy (TT10-EB-VST for EBV-positive nasopharyngeal cancer) and ICOS agonists (GSK3359609), are also in development for HNCs. Such advances look set to ensure the dominance of immunotherapy sales in HNC for the foreseeable future.

TABLE OF CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition
  • Patient segmentation
  • Risk factors
  • Symptoms
  • Diagnosis

TREATMENT

  • Referral patterns
  • Standard of care by disease progression
  • Preferred systemic therapy regimens for locally advanced disease
  • Preferred systemic therapy regimens for very advanced disease
  • Approved marketed drugs

EPIDEMIOLOGY

  • Incidence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • NICE Draft Guidance: Rejects Keytruda In Head And Neck Cancer
  • EU Approvals: Keytruda Cleared For First-Line Head And Neck Cancer
  • Keytruda Swells In Head And Neck Cancer With First-Line Claim, Full Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Tech Transfer Roundup: MD Anderson Inks Set of IO Deals Covering US, UK, Japan, China
  • Idera Pharmaceuticals Inc. and AbbVie Inc. Forged a Trial Collaboration to Study Combinations of ABBV368, Tilsotolimod, Nab-Paclitaxel, and/or ABBV181
  • Well-Funded I-Mab Gains Chinese Rights to MacroGenics' Enoblituzumab
  • Immuno-Oncology Firm Elicio Launches, Raises $30m in First Round
  • Immunomedics Inc. Granted Everest Medicines Ltd. Exclusive Rights to Develop, Register, and Sell Sacituzumab Govitecan in Asia

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

  • Standard of care shifting to immunotherapies
  • Keytruda's dominant position bolstered by label expansions
  • Immunotherapies compete for approval in newly diagnosed HNSCC
  • Growing interest in combination immunotherapies in recurrent/metastatic HNSCC
  • Other novel approaches lag behind checkpoint inhibitors

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • Bavencio for Head and Neck Cancer (March 13, 2020)
  • Debio 1143 for Head and Neck Cancer (September 30, 2019)
  • Monalizumab for Head and Neck Cancer (September 30, 2019)
  • ABBV-368 for Head and Neck Cancer (September 4, 2019)
  • Enoblituzumab for Head and Neck Cancer (July 10, 2019)
  • SD-101 for Head and Neck Cancer (June 1, 2019)
  • ASP-1929 for Head and Neck Cancer (June 1, 2019)
  • Keytruda for Head and Neck Cancer (May 31, 2019)
  • Imfinzi for Head and Neck Cancer (May 15, 2019)
  • Ibrance for Head and Neck Cancer (May 15, 2019)
  • Sacituzumab Govitecan for Head and Neck Cancer (April 29, 2019)
  • Opdivo for Head and Neck Cancer (April 25, 2019)
  • Imfinzi for Head and Neck Cancer (December 7, 2018)
  • Enoblituzumab for Head and Neck Cancer (November 9, 2018)
  • Tipifarnib for Head and Neck Cancer (October 22, 2018)
  • Keytruda for Head and Neck Cancer (October 22, 2018)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: TNM classifications for HNSCCs
  • Figure 2: Trends in incident cases of head and neck cancer, 2018-27
  • Figure 3: Overview of pipeline drugs for head and neck cancer in the US
  • Figure 4: Pipeline drugs for head and neck cancer, by company
  • Figure 5: Pipeline drugs for head and neck cancer, by drug type
  • Figure 6: Pipeline drugs for head and neck cancer, by classification
  • Figure 7: Probability of success in the head and neck cancer pipeline
  • Figure 8: Clinical trials in head and neck cancer
  • Figure 9: Top 10 drugs for clinical trials in head and neck cancer
  • Figure 10: Top 10 companies for clinical trials in head and neck cancer
  • Figure 11: Trial locations in head and neck cancer
  • Figure 12: Head and neck cancer trials status
  • Figure 13: Head and neck cancer trials sponsors, by phase
  • Figure 14: Datamonitor Healthcare's drug assessment summary for head and neck cancer
  • Figure 15: Market dynamics in head and neck cancer
  • Figure 16: Future trends in head and neck cancer
  • Figure 17: Debio 1143 for Head and Neck Cancer: Phase I/II - LA-SCCHN (September 30, 2019)
  • Figure 18: Monalizumab for Head and Neck Cancer: Phase Ib/II - w/Cetuximab (US and EU) (September 30, 2019)
  • Figure 19: ASP-1929 for Head and Neck Cancer: Phase I/IIa - w/PIT (June 1, 2019)
  • Figure 20: Keytruda for Head and Neck Cancer: Phase III - KEYNOTE-048 (May 31, 2019)
  • Figure 21: Imfinzi for Head and Neck Cancer: Phase III - EAGLE (+/- Tremelimumab) (May 15, 2019)
  • Figure 22: Ibrance for Head and Neck Cancer: Phase II - PALATINUS (w/Cetuximab) (May 15, 2019)
  • Figure 23: Opdivo for Head and Neck Cancer: Phase II - CheckMate-714 (April 25, 2019)
  • Figure 24: Imfinzi for Head and Neck Cancer: Phase III - EAGLE (+/- Tremelimumab) (December 7, 2018)
  • Figure 25: Enoblituzumab for Head and Neck Cancer: Phase I - w/Pembrolizumab or MGA012 (Solid Tumors) (November 9, 2018)
  • Figure 26: Keytruda for Head and Neck Cancer: Phase III - KEYNOTE-048 (October 22, 2018)
  • Figure 27: Key upcoming events in head and neck cancer

LIST OF TABLES

  • Table 1: Head and neck cancer: ICD-10 diagnosis codes
  • Table 2: Recommended (category 1) chemotherapy regimens for locally advanced disease, by origin of primary tumor
  • Table 3: Preferred systemic therapy regimens for very advanced disease, by origin of primary tumor
  • Table 4: Approved marketed drugs for head and neck cancer
  • Table 5: Incident cases of head and neck cancer, 2018-27
  • Table 6: Incident cases of head and neck cancer, by gender, 2018
  • Table 7: Marketed drugs for head and neck cancer
  • Table 8: Pipeline drugs for head and neck cancer in the US
  • Table 9: Historical global sales, by drug ($m), 2015-19
  • Table 10: Forecasted global sales, by drug ($m), 2020-24
  • Table 11: Bavencio for Head and Neck Cancer (March 13, 2020)
  • Table 12: Debio 1143 for Head and Neck Cancer (September 30, 2019)
  • Table 13: Monalizumab for Head and Neck Cancer (September 30, 2019)
  • Table 14: ABBV-368 for Head and Neck Cancer (September 4, 2019)
  • Table 15: Enoblituzumab for Head and Neck Cancer (July 10, 2019)
  • Table 16: SD-101 for Head and Neck Cancer (June 1, 2019)
  • Table 17: ASP-1929 for Head and Neck Cancer (June 1, 2019)
  • Table 18: Keytruda for Head and Neck Cancer (May 31, 2019)
  • Table 19: Imfinzi for Head and Neck Cancer (May 15, 2019)
  • Table 20: Ibrance for Head and Neck Cancer (May 15, 2019)
  • Table 21: Sacituzumab Govitecan for Head and Neck Cancer (April 29, 2019)
  • Table 22: Opdivo for Head and Neck Cancer (April 25, 2019)
  • Table 23: Imfinzi for Head and Neck Cancer (December 7, 2018)
  • Table 24: Enoblituzumab for Head and Neck Cancer (November 9, 2018)
  • Table 25: Tipifarnib for Head and Neck Cancer (October 22, 2018)
  • Table 26: Keytruda for Head and Neck Cancer (October 22, 2018)